Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
about
Family History of Alzheimer's Disease is Associated with Impaired Perceptual Discrimination of Novel Objects.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Tau PET imaging: present and future directions.Neuronal Cell Death and Degeneration through Increased Nitroxidative Stress and Tau Phosphorylation in HIV-1 Transgenic Rats.Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.Metabolic relationship between diabetes and Alzheimer's Disease affected by Cyclo(His-Pro) plus zinc treatment.Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET studyWhole Genome Expression Analysis in a Mouse Model of Tauopathy Identifies MECP2 as a Possible Regulator of Tau Pathology.PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain NetworksRelationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid BiomarkersAV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure.History and future technical innovation in positron emission tomography.Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.P450 Eicosanoids and Reactive Oxygen Species Interplay in Brain Injury and Neuroprotection.Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's DiseaseDefining imaging biomarker cut points for brain aging and Alzheimer's disease.Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition.Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials.Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease.AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease.18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum.Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy.The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition.Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathiesEntorhinal Cortex: Antemortem Cortical Thickness and Postmortem Neurofibrillary Tangles and Amyloid Pathology.Alzheimer's drug-development pipeline: 2016.Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's caseThe emerging role of PET imaging in dementia.Imaging of glia activation in people with primary lateral sclerosis.Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer's disease.Entorhinal tau pathology, episodic memory decline and neurodegeneration in aging.Alzheimer's disease disrupts alpha and beta-band resting-state oscillatory network connectivity.
P2860
Q33556053-7C7E2121-0E5D-4870-A1FE-238A1958CA1AQ33556068-97E5E6F8-2EE7-459A-B1FF-ABAC5B1C26A4Q34680852-D1E5E176-13A9-45C6-9BD4-7CCF0225ACC2Q36255465-334C783B-326D-48C3-B7BF-14F4CDC678B0Q37410164-59F0A919-1985-4789-9C19-F76A446DC185Q37511619-66813DD3-C1C8-49A6-88E1-3E29710A5856Q37569276-D4BD5F42-8CFC-4AC1-AC50-32089792F76AQ37600680-81DC6C6C-E372-4612-AF5B-4A679F7458D3Q37707241-C16AC62A-2E0C-4F9B-BDE5-ED5DC37713C8Q37718557-584F2CC1-FC5C-4FDA-8357-9428D9E31FBCQ37731919-B08283F3-A42A-42F2-9E9A-BDD5B6C80290Q37739881-96CE8502-7C89-4381-82BD-975AD9A48DD7Q38628805-F36103B3-5FB0-4F4C-A9BE-36BF72A3E216Q38653494-93A4595C-F3AA-4907-B3ED-906957C28298Q38731565-0FF62304-AC00-48AB-BE50-2EC0803687BEQ38739937-03878FD0-03BE-4CD2-A083-A1EED0B877AEQ38744600-681CD417-06E2-413C-86B0-0FE9A037013FQ38760663-4D1958B0-2732-47C9-9B83-5BE706FE7E07Q38803637-362BE8AD-79EA-4F95-8585-885D9AF1EB4EQ38812890-554EB7A0-C6C2-4238-8B39-6EB2CFFE6687Q38979999-1F1BCAA0-B527-493A-91D9-8F12F2648F9BQ38990773-AEEC7921-8B59-48FD-8CDD-DBE654B6137CQ39016306-BCE11EF4-0D3B-4759-ADF9-5046238ACF2AQ39451605-9BDEA770-5A65-4778-ABDF-7F1F1451F4B5Q40239437-98129C11-BA64-45A5-B06F-F6217BCA2539Q41496810-A079DB72-7AF9-4456-85BF-09F0A001B532Q41600997-001D0634-BA95-40BA-A673-5784330BAE1EQ41654319-AC9D313B-2F4D-4EE2-A244-2C5CD712E3B2Q41695282-C02B072B-4116-4CBC-A0D8-B61E79E9EA89Q42279018-2264C486-B07A-4A91-B9EC-07AE4726A1C5Q42371467-666407CA-AFCA-4662-82B8-CBF48DA8FD24Q42619991-65F5C544-59E7-4F26-A529-1C701CF46978Q42656263-E71CD644-2060-4A38-87C3-1661E0ACE98CQ42672461-D51AD0C5-E5ED-451D-A966-315274FF13CBQ42701971-FBF2311C-08FE-46F5-80F8-01CAD3034DF3Q44728742-2EB2D8A8-2EF3-410D-8894-0C522975FF76Q45974423-74E27ED6-705E-4525-AA73-11072982CB92Q46003126-79CD483F-9021-4A7E-A74F-AEB73E3D1DBCQ46075858-67E1F618-6F13-44DB-92AF-0549E6F5A704Q46323013-36C4E207-9DF8-46E7-AF6A-B2A77D5B4C0F
P2860
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
@ast
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
@en
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
@nl
type
label
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
@ast
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
@en
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
@nl
prefLabel
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
@ast
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
@en
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
@nl
P2093
P2860
P50
P1476
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
@en
P2093
Anne M Fagan
Beau M Ances
Christopher Owen
David M Holtzman
Jason Hassenstab
John C Morris
Jon Christensen
Matthew R Brier
Nigel J Cairns
P2860
P304
P356
10.1126/SCITRANSLMED.AAF2362
P407
P577
2016-05-01T00:00:00Z